BioCryst losses soar to $32.7M in 2010, including $9.1M in 4Q
Durham County, N.C. —
Boosted by federal support for development of a pandemic flu vaccine, Biocryst reported a $13.5 million loss a year earlier.
In the fourth quarter, the firm reported a loss of $9.1 million, or 20 cents per share. A year earlier, boosted by federal payments for the development of a pandemic vaccine, BioCryst reported a $15.2 million quarterly profit.
The company's research and development costs climbed to $82.5 million in 2010 from $72.3 million a year earlier. General operating expenses also increased, hitting $14.2 million compared to $11.5 million in 2009.
Revenues fell to $63.5 million from $74.6 million in 2009.
For the full earnings report and a recap of 2010, read here.
Get the latest news alerts: Follow WRAL Tech Wire at Twitter.
Log in or upgrade to view WRALTechWire Insider content
Please Log In to add a comment.
Best of TechWire Insider
- Durham's high-tech infrastructure, talent lure Virginia company
- Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy
- Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows
- Titans of tech seek to excite UNC, Duke grads about a future beyond themselves
- Triangle politician tries to accelerate crowdfunding; bill passes first hurdle